Benson L - Search Results

1

Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.

Becher PM, Savarese G, Benson L, Dahlström U, Karlström P, Mol PGM, Metra M, Bhatt DL, Pitt B, Lund LH. Becher PM, et al. Among authors: benson l. Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):343-352. doi: 10.1093/ehjcvp/pvad012. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36718512

2

Association of candesartan vs losartan with all-cause mortality in patients with heart failure.

Eklind-Cervenka M, Benson L, Dahlström U, Edner M, Rosenqvist M, Lund LH. Eklind-Cervenka M, et al. Among authors: benson l. JAMA. 2011 Jan 12;305(2):175-82. doi: 10.1001/jama.2010.1949. JAMA. 2011. PMID: 21224459

3

Losartan vs candesartan for heart failure.

Lund LH, Benson L. Lund LH, et al. Among authors: benson l. JAMA. 2012 Jul 25;308(4):336; author reply 336-7. doi: 10.1001/jama.2012.7642. JAMA. 2012. PMID: 22820775 No abstract available.

4

Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction.

Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C, Alehagen U. Lund LH, et al. Among authors: benson l. Eur Heart J. 2013 Feb;34(7):529-39. doi: 10.1093/eurheartj/ehs305. Epub 2012 Oct 4. Eur Heart J. 2013. PMID: 23041499

5

Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.

Lund LH, Benson L, Dahlström U, Edner M. Lund LH, et al. Among authors: benson l. JAMA. 2012 Nov 28;308(20):2108-17. doi: 10.1001/jama.2012.14785. JAMA. 2012. PMID: 23188027

6

Renin-Angiotensin system antagonists and mortality in patients with heart failure--reply.

Lund LH, Benson L. Lund LH, et al. Among authors: benson l. JAMA. 2013 Mar 20;309(11):1107-8. doi: 10.1001/jama.2013.1975. JAMA. 2013. PMID: 23512046 No abstract available.

7

Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center?

Thorvaldsen T, Benson L, Ståhlberg M, Dahlström U, Edner M, Lund LH. Thorvaldsen T, et al. Among authors: benson l. J Am Coll Cardiol. 2014 Feb 25;63(7):661-671. doi: 10.1016/j.jacc.2013.10.017. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24161453 Free article.

8

Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.

Thorvaldsen T, Benson L, Hagerman I, Dahlström U, Edner M, Lund LH. Thorvaldsen T, et al. Among authors: benson l. Int J Cardiol. 2014 Jul 15;175(1):55-61. doi: 10.1016/j.ijcard.2014.04.243. Epub 2014 Apr 29. Int J Cardiol. 2014. PMID: 24820737

9

Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure.

Linde C, Ståhlberg M, Benson L, Braunschweig F, Edner M, Dahlström U, Alehagen U, Lund LH. Linde C, et al. Among authors: benson l. Europace. 2015 Mar;17(3):424-31. doi: 10.1093/europace/euu205. Epub 2014 Aug 27. Europace. 2015. PMID: 25164429

10

Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14,713 patients in the Swedish Heart Failure Registry.

Lund LH, Benson L, Ståhlberg M, Braunschweig F, Edner M, Dahlström U, Linde C. Lund LH, et al. Among authors: benson l. Eur J Heart Fail. 2014 Oct;16(10):1073-81. doi: 10.1002/ejhf.162. Epub 2014 Sep 8. Eur J Heart Fail. 2014. PMID: 25201219 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,133 results

Search Page

Filters